Effect of Direct Acting Antivirals on the Pharmacokinetics of Calcineurin Inhibitors
Thibaut Gelé1, Aurélie Barrat-Train1, Audrey Colly2,3, Claire Laforet4, Rodolphe Aný5, Georges-Philippe Pageaux6, Jean-Charles Duclos-Vallée6, Marie-Anne Taburet1 and the ANRS CO23 CUPIL study group
1AP-HP, Paris Sud Univ Hosp, Bicêtre Hosp, Le Kremlin-Bicêtre, France; 2AP-HP, Paris Sud Univ Hosp, Paul-Brousse Hosp, Villejuif, France; 3DHU Hepatovir, Villejuif, France; 4Rennes Univ Hosp, Pitié Salpêtrière Hosp, Paris; 5Nice Univ Hosp, Archel Hosp, Nice, France; 6Montpellier Univ Hosp, St-Etienne Hosp, Montpellier, France

Abstract

Inhibitors
Inhibitors
severe
initiation
Hosp, Paul
69 (56
for
geometric
Antivirals
therapy:
mg
selected
indicated,
in
backbone
90
describe
68 (37
2
steady
of
drug
these
56 (40
and
ratio
at
hepatitis
Cl
760 (330
on
treatment
W
TAC
tacrolimus and cyclosporine Cl/F
steady
QD,
post
analogs)
were
patient
follow
increased
and
non
pts
on
79 (58
; 7
increased
Pt
transplant
to
to
collections
dosing
and
cyclosporine
Cl/F
need
after
in
20
explaining
state
2
C
results
at
immunosuppressive
cohort,
anti
DAA
drug
warranting
virus
Cyclosporine
at
decrease
QD
concentrations
or
(D/(
and
direct
Direct
informed
Apparent
unchanged
Hosp
sponsored
(GMR)
in
statistical
genotype
(RBV)
on
before
controls
drugs
D/(
before
optimized
the
per
be
DAAs,
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiretroviral
the
trough
cohort
TAC
immunosuppressive
the
infected
an
Despite
quality
included
bioequivalence
Patients
indicated,
Cl/F
antivirals
or
Trough
(HCV)
These
them
either
to
increased
78 (53
has
CUPILT
and
sofosbuvir
of
otherwise
concentration
BID (n=12)
acting
TAC
immunosuppressive
3
Antiret...